Phase II study of everolimus for recurrent or progressive pediatric ependymoma.
Daniel C BowersVeena RajaramMatthias A KarajannisSharon L GardnerJack Meng-Fen SuPatricia BaxterSonia PartapLaura J KlessePublished in: Neuro-oncology advances (2023)
Everolimus does not appear to have activity for children with recurrent or progressive PF-A ependymoma.